2013-08-27 14:20:49 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Immunomedics, Inc. (IMMU) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Immunomedics, Inc. (IMMU). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Immunomedics, Inc. investor.
Report Summary: Immunomedics, Inc. is a low quality company with a neutral outlook. Immunomedics, Inc. has weak business growth and is run by inefficient management. The trend in Immunomedics, Inc. fair value exchange rate against its closest rated-competitor, Anacor Pharmaceuticals Inc, has been depreciating over the past 2 weeks. When compared to its closest competitor, Immunomedics, Inc. shows similar undervaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its three components - business, management and price,
performing an in-depth analysis of Immunomedics, Inc. for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.